DRUG INTERACTIONS
No formal drug interaction studies have been conducted with Interferon beta-1b. In the placebo controlled studies in MS, corticosteroids or ACTH were administered for treatment of relapses for periods of up to 28 days in patients (N=664) receiving Interferon beta-1b.
|
OVERDOSAGE
Safety of doses higher than 0.25 mg every other day has not been adequately evaluated. The maximum amount of Interferon beta-1b that can be safely administered has not been determined.
|
CONTRAINDICATIONS
EXTAVIA is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, Albumin (Human), USP, or any other component of the formulation.
|
REFERENCES
1. Poser CM, et al. Ann Neurol 1983; 13(3): 227-231.
2. Kurtzke JF. Neurology 1983; 33(11): 1444-1452.
|
|
|
